IL1B and COVID-19: The avoidance of hypercytokinemia is a pivotal therapeutic aim in COVID-19, similar to AID, and cytokine targeting agents, such as anti-IL-1 treatment, anti-IL-6 treatment or Janus kinase inhibitors may be promising [12,13,15].